Echo Street Capital Management LLC Exelixis, Inc. Transaction History

Echo Street Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$16.3 - $19.41 $61,565 - $73,311	-3,777 Reduced 18.44%	16,708 $324,000
Q4 2022 Feb 13, 2023	SELL	$14.96 - $17.39 $409,156 - $475,616	-27,350 Reduced 57.18%	20,485 $328,000
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $750,052 - $1.07 Million	47,835 New	47,835 $750,000
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $407,642 - $563,081	-25,735 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $1.1 Million - $1.42 Million	-67,247 Reduced 72.32%	25,735 $544,000
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $1.14 Million - $1.62 Million	63,253 Added 212.77%	92,982 $1.69 Million
Q1 2021 May 17, 2021	BUY	$20.53 - $25.22 $610,336 - $749,765	29,729 New	29,729 $672,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Echo Street Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Echo Street Capital Management LLC with notifications on news.